Plasma proteins are derived from human blood and are vital for treating a number of illnesses, such as haemophilia, immune deficiencies, and other uncommon diseases. These medicinal goods, which include albumin, clotting factors, and immunoglobulins, are essential for controlling and reducing the symptoms of a variety of illnesses. The market includes every stage of the value chain, from the extraction and fractionation of plasma to the production and distribution of medicines derived from plasma.



Global Plasma Protein Therapeutics report scope and segmentation.

Report Attribute


Estimated Market Value (2023)

USD 25.85 billion

Projected Market Value (2032)

USD 41.73 billion

Base Year


Forecast Years

2024 – 2032

Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment- Based on By Product, By Application, & Region.

Segments Covered

By Product, By Application & By Region.

Forecast Units

Value (USD Billion or Million), and Volume (Units)

Quantitative Units

Revenue in USD million/billion and CAGR from 2023 to 2032.

Regions Covered

North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Countries Covered

U.S., Canada, Mexico, U.K., Germany, France, Italy, Spain, China, India, Japan, South Korea, Brazil, Argentina, GCC Countries, and South Africa, among others.

Report Coverage

Market growth drivers, restraints, opportunities, Porter’s five forces analysis, PEST analysis, value chain analysis, regulatory landscape, market attractiveness analysis by segments and region, company market share analysis.

Delivery Format

Delivered as an attached PDF and Excel through email, according to the purchase option.


Global Plasma Protein Therapeutics dynamics

The ageing of the world's population and the rising prevalence of chronic illnesses are major factors driving the rise in demand for therapies derived from plasma. Technological developments in biotechnology and manufacturing processes facilitate the creation of safer and more effective products, which in turn drives market expansion. Furthermore, greater uptake and market penetration are being fostered by patients' and healthcare professionals' growing awareness of these therapies, particularly in emerging markets.

However, the industry faces challenges such as stringent regulatory frameworks and ethical concerns related to the collection of human plasma. Meeting regulatory requirements poses a constant challenge for market participants, impacting product development timelines and market entry strategies. Ethical considerations surrounding plasma donation, including issues related to compensation and donor consent, add a layer of complexity to the supply chain. Additionally, the market is vulnerable to possible supply chain disruptions, which can include anything from changes in the rates of plasma donation to logistical difficulties in the collection and processing of plasma.


Global Plasma Protein Therapeutics drivers

  • Increasing Prevalence of Chronic and Rare Diseases

A major factor propelling the global market for plasma protein therapeutics is the increasing incidence of uncommon and chronic illnesses across the globe. The prevalence of diseases like immunological deficiencies, haemophilia, and neurological disorders is rising as the world's population ages. The increase in patient volume fuels the need for therapeutics derived from plasma, advancing efforts in research and development to bring new, more potent treatments to market. The market is driven by the growing number of patients with unmet medical needs, which pushes pharmaceutical and biotechnology companies to expand their product lines and innovate in order to treat a wider range of illnesses.

  • Technological Advancements and Product Innovation

The continuous advancement of biotechnological processes and manufacturing techniques represents a significant driver for the Global Plasma Protein Therapeutics market. Ongoing research efforts focus on improving the safety, efficacy, and scalability of plasma-derived products. Technological innovations contribute to enhanced purification methods, reduced risk of contamination, and increased yields during the fractionation process. Improved manufacturing processes not only ensure the production of high-quality therapeutics but also facilitate cost-effective and efficient mass production. These advancements bolster the competitiveness of companies within the market, enabling them to meet the growing demand for plasma-derived therapies while maintaining stringent quality standards.



  • Regulatory Complexities and Compliance Challenges

The industry for plasma-derived medicines is severely constrained by strict regulatory frameworks. Market participants face ongoing challenges in meeting compliance requirements, which necessitate significant investments in research, development, and regulatory affairs. Regulatory obstacles can impede the speed at which businesses can adapt to changing medical needs by delaying product approvals and market entry. To ensure successful market access, a comprehensive and flexible regulatory strategy is necessary due to the intricacy of navigating diverse regulatory landscapes across different regions.

  • Ethical Concerns and Supply Chain Vulnerabilities

The global plasma protein therapeutics market is constrained by ethical issues surrounding the harvesting of human plasma. Important factors that require careful consideration include things like providing donors with fair compensation, obtaining their informed consent, and guaranteeing the safety of the donor pool. Upholding the public's confidence and preserving a strong supply chain depend on addressing these ethical issues. The supply chain itself is also susceptible to interruptions, which can take many different forms, from variations in donor involvement to practical difficulties in the distribution, processing, and collection of plasma. In order to satisfy the increasing demand for plasma-derived medicines, it is imperative to maintain a reliable and morally sound supply chain.


  • Opportunities:

Emerging Markets and Untapped Potential

Opportunities abound in emerging markets, where improving healthcare infrastructure, rising healthcare expenditure, and increasing awareness of plasma-derived therapies present untapped potential. These regions offer a growing patient population with unmet medical needs, creating a favourable environment for market expansion. Companies that strategically position themselves to enter and navigate these emerging markets stand to benefit from early-mover advantages and a potentially lucrative patient base.


Segment Overview

  • By Product

The global plasma protein therapeutics market is segmented based on different product categories, each serving distinct therapeutic purposes. Albumin, a key component of blood plasma, finds applications in treating conditions such as burns, liver disease, and surgical complications. Its ability to maintain oncotic pressure and bind to various substances makes it a versatile therapeutic agent. Immunoglobulins, derived from plasma, play a crucial role in treating primary immunodeficiency disorders by boosting the immune system. These antibodies are essential for patients with compromised immune function, providing passive immunity against infections. Plasma-derived Factor VIII, another significant product segment, addresses the needs of individuals with hemophilia. This clotting factor is vital for managing bleeding episodes in hemophiliacs, contributing to improved quality of life. The "Others" category encompasses a diverse range of plasma-derived products, including clotting factors and enzyme replacements, catering to specific medical conditions and expanding the therapeutic options available within the market.

  • By Application  

The market is further categorized based on applications, reflecting the diverse medical conditions that plasma protein therapeutics address. Hemophilia, a genetic disorder characterized by impaired blood clotting, constitutes a substantial application segment. Plasma-derived Factor VIII and other clotting factors are essential in managing and preventing bleeding episodes in individuals with hemophilia, significantly improving patient outcomes. Primary Immunodeficiency Disorders (PIDD) represent another critical application area. Immunoglobulins play a pivotal role in treating individuals with weakened immune systems, enhancing their ability to fight infections. Idiopathic Thrombocytopenic Purpura (ITP), a disorder characterized by low platelet counts, is addressed through various plasma-derived therapies that aid in managing and regulating platelet levels. The "Others" category includes additional applications such as alpha-1 antitrypsin deficiency and hereditary angioedema, illustrating the broad spectrum of medical conditions treated with plasma protein therapeutics. These applications collectively underscore the versatility of plasma-derived products, catering to a range of rare and chronic diseases, and highlight the ongoing efforts within the industry to expand treatment options for patients across diverse medical contexts.


Global Plasma Protein Therapeutics Overview by Region

The global market for plasma protein therapeutics is geographically heterogeneous, with North America and Europe occupying leading positions. These areas greatly contribute to market growth because they have established healthcare infrastructures, high levels of awareness, and advantageous reimbursement policies. Due in large part to a strong presence of major industry players, a large patient population with chronic illnesses, and a robust regulatory framework, North America—led by the United States—dominates the market. Europe is closely behind, with nations like the United Kingdom and Germany making significant investments in R&D to support the market's growth.

While North America and Europe remain key players, Asia-Pacific is emerging as a pivotal region for the Plasma Protein Therapeutics market. Increasing healthcare expenditure, improving healthcare infrastructure, and a rising prevalence of chronic diseases in countries such as China and India are fuelling market growth. Additionally, Latin America and the Middle East & Africa are witnessing a gradual uptake of plasma-derived therapies, supported by evolving healthcare systems and a growing awareness of advanced treatment options.


Global Plasma Protein Therapeutics market competitive landscape

Major industry players such as CSL Behring, Grifols, Shire (a Takeda company), and Octapharma demonstrate a strong global presence with extensive product portfolios covering immunoglobulins, clotting factors, and albumin. These companies leverage their comprehensive research and development capabilities, vast manufacturing infrastructure, and established distribution networks to maintain a competitive edge in the market.

Biotechnology firms like Baxalta and Bio Products Laboratory (BPL) contribute to the competitive landscape with a focus on innovation and the development of novel plasma-derived products. These companies often bring a nimble and specialized approach to the market, emphasizing cutting-edge technologies to enhance product safety, efficacy, and patient outcomes. Additionally, strategic collaborations and partnerships with research institutions, healthcare organizations, and other industry players are common strategies employed to foster innovation and expand market reach.

Specialized players, including companies like Kedrion and Kamada, often carve out niche positions within specific therapeutic areas, offering unique plasma-derived therapies to address rare diseases and conditions. This diverse mix of competitors fosters a collaborative environment, encouraging joint ventures and licensing agreements to optimize research efforts and strengthen market presence.



Global Plasma Protein Therapeutics Recent Developments

  • May 2023, Biotest AG obtained marketing authorizations to introduce Cytotect, a CMV-hyper immunoglobulin, in five new markets. These include the Czech Republic, Slovakia, Lithuania, Ireland, and Romania, expanding its market presence to a total of 28 countries.


Scope of global Plasma Protein Therapeutics report

Global Plasma Protein Therapeutics report segmentation



By Product

  • Albumin
  • Immunoglobulin
  • Plasma-derived Factor VIII
  • Others

By Application

  • Hemophilia
  • Primary Immunodeficiency Disorder (PIDD)
  • Idiopathic Thrombocytopenic Purpura (ITP)
  • Others

By Geography

  • North America (USA, and Canada)
  • Europe (UK, Germany, France, Italy, Spain, Russia and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East & Africa (South Africa, GCC, and Rest of Middle East & Africa)

Customization Scope

  • Available upon request


  • Available upon request


Objectives of the Study

The objectives of the study are summarized in 5 stages. They are as mentioned below:

  • Global Plasma Protein Therapeutics size and forecast: To identify and estimate the market size for global Plasma Protein Therapeutics market segmented by Product, By Application and by region. Also, to understand the consumption/ demand created by consumers between 2024 and 2032.
  • Market Landscape and Trends: To identify and infer the drivers, restraints, opportunities, and challenges for global Plasma Protein Therapeutics
  • Market Influencing Factors: To find out the factors which are affecting the market of global Plasma Protein Therapeutics among consumers.
  • Company Profiling: To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company's past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.